Targeting ARID1A mutations in cancer

Jaren Mullen1, Shumei Kato1, Jason K Sicklick2

  • 1Center for Personalized Cancer Therapy, UCSD Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.

Cancer Treatment Reviews
|October 7, 2021
PubMed

Insights

Mutations in the ARID1A gene, a key component of the SWI/SNF complex, are common in cancers like ovarian clear cell and uterine endometrioid types. These alterations impact gene expression and suggest potential therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The SWI/SNF chromatin remodeling complex is frequently altered in human cancers, with ARID1A being the most commonly mutated subunit.
  • ARID1A gene alterations lead to loss of function and are observed in approximately 6% of all cancers, notably ovarian clear cell (45%) and uterine endometrioid (37%) cancers.

Purpose of the Study:

  • To review the critical role of ARID1A in gene expression regulation relevant to oncogenesis and tumor suppression.
  • To identify potential therapeutic strategies and drug targets for ARID1A-altered cancers.

Main Methods:

  • Literature review and analysis of existing data on ARID1A mutations and their functional consequences.
  • Examination of ARID1A's involvement in key cellular pathways and its implications for cancer treatment.

Main Results:

  • ARID1A mutations affect critical pathways including PI3K/AKT/mTOR, immune response, EZH2 activity, and DNA damage response.
  • ARID1A alterations are associated with resistance to platinum chemotherapy and endocrine therapies.

Conclusions:

  • Targeting pathways regulated by ARID1A, such as mTOR and EZH2, and utilizing immune checkpoint blockade may benefit patients with ARID1A-altered cancers.
  • Understanding ARID1A's role is crucial for developing novel therapeutic approaches and overcoming treatment resistance.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K